ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS

Reuters
2025.12.01 13:52
portai
I'm PortAI, I can summarize articles.

Actinium Pharmaceuticals Inc :ACTINIUM PHARMACEUTICALS ANNOUNCES ATNM-400 DATA DEMONSTRATING POTENT EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER AND ABILITY TO OVERCOME ENDOCRINE AND HER2-TARGETED THERAPY RESISTANCE BEING PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer